Please select the option that best describes you:
Topics:
Breast Cancer • Gynecologic Oncology • Genitourinary Cancers • Medical Oncology • Breast Cancer, Metastatic
What is your approach to supportive management of PARP inhibitor associated anemia?
What strategies may help mitigate this toxicity, especially if a patient has achieved disease control on a PARPi? Is there a role for an ESA?